OUP (Osage University Partners)
OUP is a venture capital fund investing in start-ups that commercialize university research.
Business Model: Education
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed OUP (Osage University Partners) Information
Geographic Data
Address: 50 Monument Road
City: Bala Cynwyd
State: CA
Zip: 19004
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$350M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
4,859,126Website Global Rank
1,766Website Monthly Traffic
Twitter Followers
Description
Osage University Partners is a venture capital firm focused on investing in startups that are commercializing university technologies. Osage partners with research universities to invest in their innovative startups shareing its investment profit with partner institutions. The firm invests in software, hardware, and life science companies at all stages of company development. To date, it has partnered with over 80 universities, including 36 of the top 50 U.S. institutions by research expenditures, and has invested in over 50 of their spinouts.
Contact Phone:
+14844342255
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2019 | Vor Biopharma | Series A | 42M |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 10/2019 | Cyteir Therapeutics | Series B | 40.2M |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 3/2016 | Capella BioScience | Series A | 15.5M |
| 3/2016 | StreetLight Data | Series B | 10M |
| 1/2023 | Hack The Box | Series B | 0 |
| 4/2018 | Synthorx | Series C | 63M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 10/2012 | Mirna Therapeutics | Series C | 34.5M |
| 1/2006 | Avid Radiopharmaceuticals | Series A | 0 |
| 2/2019 | KenSci | Series B | 22M |
| 4/2018 | SiFive | Series C | 50.6M |
| 12/2013 | Infinio | Series B | 12M |
| 5/2017 | Hyalex Orthopaedics | Series A | 16M |
| 1/2021 | Delfi Diagnostics | Series A | 0 |
| 1/2021 | Coho Therapeutics | Seed Round | - |
| 3/2017 | Spero Therapeutics | Series C | 51.7M |
| 10/2012 | Clinipace | Series C | 9M |
| 10/2019 | IonQ | Series B | 55M |
| 8/2020 | Censys | Series A | 15.5M |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 12/2015 | Everactive | Series B | 16.5M |
| 6/2022 | MicroTransponder | Series E | 0 |
| 11/2012 | Cardioxyl Pharmaceuticals | Series B | 28M |
| 4/2018 | NuMat Technologies | Series B | 0 |
| 9/2021 | Corelight | Series D | 0 |
| 5/2016 | Aptinyx | Series A | 0 |
| 6/2022 | Nikola Labs | Series A | 0 |
| 7/2019 | Menlo Security | Series D | 75M |
| 11/2014 | Menlo Security | Series A | 10.5M |
| 11/2020 | Menlo Security | Series E | 100M |
| 7/2021 | Glyphic Biotechnologies | Seed | 6M |
| 7/2014 | Faraday Pharmaceuticals | Series A | - |
| 3/2015 | Kura Oncology | Private Equity Round | 60M |
| 4/2015 | Mirna Therapeutics | Series D | 0 |
| 9/2021 | Vanqua Bio | Series B | 85M |
| 3/2018 | Cyteir Therapeutics | Series B | 29M |
| 11/2015 | Body Labs | Series A | 0 |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 11/2022 | Escient Pharmaceuticals | Series C | 120M |
| 1/2011 | Tangent Medical Technologies | Seed Round | 2.5M |
| 7/2018 | Seismos | Venture Round | 0 |
| 6/2018 | Ambiq Micro | Venture Round | 0 |
| 4/2020 | Atsena Therapeutics | Venture Round | 8.2M |
| 1/2021 | Neuros Medical | Series B | 0 |
| 3/2022 | Brimstone Energy | Series A | 0 |
| 6/2012 | Tangent Medical Technologies | Venture Round | 7.9M |
| 2/2017 | PMV Pharmaceuticals | Series B | 74M |
| 5/2010 | Gevo | Series D | 0 |
| 9/2020 | Nido Biosciences | Venture Round | 18.4M |
| 8/2017 | Neuros Medical | Series A | 20M |
| 3/2015 | Paracosm | Venture Round | 812k |
| 8/2009 | Gevo | Venture Round | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 5/2018 | Beam Therapeutics | Series A | 87M |
| 3/2012 | Receptos | Venture Round | 30M |
| 5/2019 | LunaDNA | Venture Round | 4.6M |
| 9/2015 | Faraday Pharmaceuticals | Series A | 30M |
| 4/2021 | Hack The Box | Series A | 0 |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 2/2018 | CounterFlow | Seed Round | 0 |
| 4/2015 | Clarifai | Series A | 10M |
| 2/2016 | Spero Therapeutics | Series B | 30M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 12/2014 | PMV Pharmaceuticals | Series A | 30M |
| 8/2016 | Cleave Therapeutics | Series B | 0 |
| 1/2014 | Menlo Security | Seed Round | - |
| 9/2013 | Otonomy | Series C | 45.9M |
| 7/2017 | Lastline | Series C | 0 |
| 11/2011 | Cleave Therapeutics | Series A | 42M |
| 10/2020 | Q32 Bio | Series B | 60M |
| 1/2017 | Pionyr Immunotherapeutics | Series A | 8M |
| 2/2018 | Picwell | Series B | 0 |
| 10/2013 | Immune Design | Series C | 49M |
| 4/2013 | SkyTree, Inc. | Series A | 18M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 6/2020 | StreetLight Data | Series D | 15M |
| 12/2016 | Merganser Biotech | Venture Round | - |
| 8/2019 | Cleave Therapeutics | Series C | 0 |
| 8/2019 | Landos Biopharma | Series B | 60M |
| 6/2017 | Vector Launch | Series A | 0 |
| 9/2011 | Clinipace | Series C | 15M |
| 10/2017 | Everactive | Venture Round | 40.3M |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 12/2008 | Luxtera | Series D | 0 |
| 11/2012 | Tangent Medical Technologies | Series B | 8.6M |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 3/2020 | ReCode Therapeutics | Series A | 0 |
| 7/2015 | Voxel8 | Series A | 12M |
| 10/2022 | Normunity | Series A | 65M |
| 2/2014 | Guardant Health | Series A | 10M |
| 12/2015 | Enlibrium | Series A | 15M |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 11/2011 | Sera Prognostics | Series A | 19.3M |
| 6/2017 | Algorithmia | Series A | 10.5M |
| 12/2015 | Ribon Therapeutics | Venture Round | 10M |
| 6/2015 | Menlo Security | Series B | 25M |
| 1/2019 | Seismos | Venture Round | 0 |
| 12/2017 | Menlo Security | Series C | 40.3M |
| 8/2020 | Aerovate Therapeutics | Series A | 72.6M |
| 2/2016 | Ribon Therapeutics | Series A | 24M |
| 7/2021 | Verve Motion | Series A | 15M |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 7/2017 | ESCAPE Bio | Series A | 63M |
| 11/2012 | Applied Genetics Technologies Corporation | Series B | 0 |
| 11/2014 | Paracosm | Seed Round | 3.3M |
| 10/2009 | Kolltan Pharmaceuticals | Series A | 0 |
| 6/2011 | SolarBridge Technologies | Series C | 0 |
| 4/2019 | Satsuma Pharmaceuticals | Series B | 0 |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 8/2013 | Evolv Technology | Series A | 11.8M |
| 12/2020 | Atsena Therapeutics | Series A | 0 |
| 5/2012 | SolarBridge Technologies | Series D | 25M |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 3/2019 | Hyalex Orthopaedics | Series A | 17M |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 6/2019 | Artizan Biosciences | Series A | 0 |
| 3/2018 | Clinipace | Venture Round | 0 |
| 9/2015 | Selecta Biosciences | Series E | 38M |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 3/2013 | Receptos | Series B | 30M |
| 3/2021 | EGenesis | Series C | 0 |
| 3/2014 | Kolltan Pharmaceuticals | Series D | 60M |
| 6/2014 | Jibo | Seed Round | 5M |
| 11/2011 | Tangent Medical Technologies | Series A | 4.5M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 11/2017 | Quantum Circuits | Series A | 18M |
| 8/2016 | Ambiq Micro | Series D | 9.4M |
| 6/2013 | Kymeta | Series C | 50M |
| 7/2010 | MC10 | Series A | 0 |
| 3/2021 | Artizan Biosciences | Series A | 0 |
| 5/2019 | LunaPBC | Venture Round | 4.6M |
| 1/2023 | Opsys Tech | Series C | 0 |
| 10/2013 | Sideris Pharmaceuticals | Series A | 32M |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 12/2011 | Liquid Light | Series A | 5.5M |
| 7/2018 | StreetLight Data | Series C | 0 |
| 7/2015 | Picwell | Series A | 4M |
| 11/2009 | Virdante Pharmaceuticals | Series A | 30M |
| 5/2009 | Avid Radiopharmaceuticals | Series D | 0 |
| 6/2018 | Embodied | Series A | 22M |
| 10/2018 | Modis Therapeutics | Series A | 30M |
| 7/2017 | Perceptive Automata | Seed Round | 0 |
| 2/2012 | SkyTree, Inc. | Seed Round | 1.5M |
| 5/2018 | Escient Pharmaceuticals | Series A | 40M |
| 7/2008 | Immune Design | Series A | 18M |
| 2/2002 | Luxtera | Series A | 6.8M |
| 6/2010 | Corridor Pharmaceuticals | Series A | 0 |
| 10/2009 | Corridor Pharmaceuticals | Series A | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 4/2014 | Otonomy | Series D | 49M |
| 6/2011 | MC10 | Series B | 0 |
| 4/2015 | Seismos | Series A | 4M |
| 6/2019 | SiFive | Series D | 65.4M |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 5/2018 | Medisix Therapeutics | Series A | 20M |
| 9/2014 | Liquid Light | Series B | 15M |
| 7/2017 | Corelight | Series A | 9.2M |
| 7/2008 | Kolltan Pharmaceuticals | Series A | 0 |
| 11/2014 | Ambiq Micro | Series C | 15.6M |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 2/2021 | Cyteir Therapeutics | Series C | 0 |
| 8/2020 | SiFive | Series E | 0 |
| 2/2017 | Arrakis Therapeutics | Series A | 38M |
| 5/2017 | SiFive | Series B | 8.5M |
| 12/2017 | Pionyr Immunotherapeutics | Series B | 0 |
| 8/2018 | MC10 | Venture Round | 0 |
| 11/2014 | Everactive | Series A | 5.3M |
| 7/2010 | Immune Design | Series B | 32M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 8/2014 | Algorithmia | Seed Round | 2.6M |
| 6/2016 | Cell Design Labs | Equity | 34.4M |
| 10/2019 | ArsenalBio | Series A | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 11/2019 | PMV Pharmaceuticals | Series C | 0 |
| 6/2016 | Blade Therapeutics | Series B | 45M |
| 3/2018 | Dracen Pharmaceuticals | Series A | 40M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 7/2017 | IonQ | Series A | 20M |
| 9/2016 | Fortis Therapeutics | Series A | 18M |
| 3/2021 | Fortis Therapeutics | Series A | 0 |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 10/2022 | Metalenz | Series B | 0 |
| 5/2019 | Algorithmia | Series B | 25M |
| 7/2015 | Blade Therapeutics | Series A | 6.5M |
| 9/2017 | Selecta Biosciences | Post-IPO Equity | 21M |
| 3/2011 | Aerie Pharmaceuticals | Series B | 41.4M |
| 1/2016 | Kymeta | Series D | 62M |
| 8/2005 | Gevo | Series A | 500k |
| 7/2018 | Spero Therapeutics | Post-IPO Equity | 75M |
| 7/2018 | Infinite Uptime | Series A | 5M |
| 12/2012 | MC10 | Series C | 10M |
| 9/2020 | Palladio Biosciences | Series B | 20M |
| 5/2015 | Precision BioSciences | Series A | 0 |
| 1/2017 | KenSci | Series A | 8.5M |
| 12/2018 | Elementary Robotics | Seed Round | 0 |
| 10/2018 | Vector Launch | Series B | 0 |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 6/2022 | Nikola Labs | Series A | 0 |
| 6/2022 | MicroTransponder | Series E | 0 |
| 3/2022 | Brimstone Energy | Series A | 0 |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 9/2021 | Vanqua Bio | Series B | 0 |
| 9/2021 | Corelight | Series D | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
